Background: Two new agents have recently been licensed as maintenance therapy for
advanced non-small-cell lung cancer (NSCLC) by the US Food and Drug Administration …

The aim of this study was to evaluate the efficacy and safety of erlotinib as maintenance
therapy in patients with unresectable non-small cell lung cancer (NSCLC) by evidence …

Three randomized trials (SATURN, ATLAS and IFCT-GFPC 0502) have demonstrated that
the oral antiepidermal growth factor receptor tyrosine kinase inhibitor erlotinib can improve …

Background First-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) is
usually limited to four to six cycles. Maintenance therapy can delay progression and prolong …

Nowadays, advanced non-small cell lung cancer (NSCLC) is still an incurable disease.
However, recent researches on maintenance therapy have led to considerable progress …

Introduction: The concept of maintenance therapy in lung cancer has stirred a great deal of
interest over the last decade. Several randomized studies have been conducted to find out …

Lung cancer is the most common cancer worldwide with non-small cell lung cancer
(NSCLC), including squamous carcinoma, adenocarcinoma and large cell carcinoma …

Introduction Erlotinib and pemetrexed have been approved for the second-line and
maintenance treatment of non-small cell lung cancer (NSCLC). With the recommended …

Introduction Little data is available on patients with advanced non-squamous NSCLC
treated with erlotinib specifically after failure of first-line pemetrexed-containing …

Abstract Learning Objectives After completing this course, the reader will be able to:
Evaluate the relationship between EGFR mutation status and clinical outcomes reported in …